N-C200

N-C200 is an engineered recombinant protein biologic being developed by Neurocarrus for the treatment of metastatic cancer. The drug is designed using the company's proprietary protein engineering platform, which focuses on the targeted delivery of therapeutics to specific cellular environments. N-C200 is intended to target the tumor microenvironment to inhibit the progression and spread of metastatic disease. While the specific molecular targets have not been publicly disclosed, the therapeutic approach is part of a broader strategy to modulate the interactions between the nervous system and cancer cells, often referred to as the neuro-cancer axis. The program is currently in the preclinical stage of development.